Medtronic (MDT) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Medtronic (MDT)

MDT 92.65

+0.5%

Nov 10 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Backewenk who wrote (402)	11/23/1999 5:54:00 PM
From: Mike	Read Replies (1) of 687

Another analyst upped MDT target price. Look for alot more upgrades as we move forward. MDT will get approval on the Jewel AF defib device in a couple months (maybe weeks). This maybe the "old" MDT reinvented!!!!!. The biggest things from the recent announcements are: 1. S670 stent approved with Rapid exchange technology. This is HUGE. 2. Analyst are starting to see that the R&D is paying off bigtime. 3. All six aquisitions have been integrated and will pay dividends as we move forward. This is big news as MDT spent approx $8B. Good luck to all, Mike RESEARCH ALERT - Medtronic price target upped NEW YORK, Nov 23 (Reuters) - Deutsche Banc Alex. Brown said Tuesday it has raised its 12-month price target for medical device maker Medtronic Inc. <MDT.N> to $50 from a range of $42 to $46. report said raised the price following strong fiscal 2000 second quarter results, which showed profits up nearly 20 percent. report added that the results confirm its view that Medtronic has successfully integrated nearly all of the six acquisitions made in the last 12 months and is positioned to meet, and perhaps beat, Deutsche Banc's expectations going forward. Shares of Medtronic were down 13/16 at 38-1/16. 10:26 11-23-99 Copyright 1999 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. All active hyperlinks have been inserted by AOL.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next